Exact Sciences Co. (NASDAQ: EXAS) was given a new $60.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock.
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Exact Sciences Schedules First Quarter 2025 Earnings CallBusiness Wire
- Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening [Yahoo! Finance]Yahoo! Finance
- Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer ScreeningBusiness Wire
- Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
- Katie Couric shares what she wishes she knew about colon cancer before her husband died at 42 years old [Business Insider]Business Insider
EXAS
Earnings
- 2/19/25 - Miss
EXAS
Sec Filings
- 3/10/25 - Form 4
- 3/4/25 - Form 4
- 3/4/25 - Form 4
- EXAS's page on the SEC website